Nomura Asset Management Co. Ltd. Buys 5,125 Shares of Amgen Inc. (NASDAQ:AMGN)

Nomura Asset Management Co. Ltd. grew its stake in Amgen Inc. (NASDAQ:AMGN) by 1.4% during the fourth quarter, Holdings Channel reports. The firm owned 381,262 shares of the medical research company’s stock after purchasing an additional 5,125 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Amgen were worth $109,811,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Nixon Peabody Trust Co. bought a new stake in Amgen during the fourth quarter worth $447,000. Skopos Labs Inc. purchased a new stake in Amgen in the fourth quarter worth $990,000. Congress Wealth Management LLC DE grew its position in shares of Amgen by 8.9% in the fourth quarter. Congress Wealth Management LLC DE now owns 58,047 shares of the medical research company’s stock valued at $16,719,000 after purchasing an additional 4,730 shares in the last quarter. Hoylecohen LLC grew its position in shares of Amgen by 34.9% in the fourth quarter. Hoylecohen LLC now owns 4,709 shares of the medical research company’s stock valued at $1,356,000 after purchasing an additional 1,218 shares in the last quarter. Finally, HCR Wealth Advisors grew its position in shares of Amgen by 4.9% in the fourth quarter. HCR Wealth Advisors now owns 4,659 shares of the medical research company’s stock valued at $1,342,000 after purchasing an additional 219 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Down 0.2 %

Shares of NASDAQ AMGN traded down $0.66 during midday trading on Friday, hitting $305.84. The company’s stock had a trading volume of 2,425,809 shares, compared to its average volume of 2,831,793. The business’s fifty day simple moving average is $284.28 and its two-hundred day simple moving average is $285.28. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72. The firm has a market capitalization of $164.06 billion, a price-to-earnings ratio of 43.80, a price-to-earnings-growth ratio of 2.80 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.76 by $0.20. The business had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company’s revenue was up 22.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.98 EPS. On average, equities analysts predict that Amgen Inc. will post 19.46 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.94%. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the sale, the senior vice president now owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.69% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Leerink Partnrs lowered Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. StockNews.com upgraded Amgen from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Oppenheimer restated an “outperform” rating and issued a $350.00 price target on shares of Amgen in a research note on Thursday, February 1st. Royal Bank of Canada cut their price target on Amgen from $332.00 to $328.00 and set an “outperform” rating on the stock in a research note on Friday, May 3rd. Finally, Truist Financial reissued a “buy” rating and issued a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and an average price target of $305.65.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.